Wong M - Search Results

1

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass.

Recker RR, Kendler D, Recknor CP, Rooney TW, Lewiecki EM, Utian WH, Cauley JA, Lorraine J, Qu Y, Kulkarni PM, Gaich CL, Wong M, Plouffe L Jr, Stock JL. Recker RR, et al. Among authors: wong m. Bone. 2007 Apr;40(4):843-51. doi: 10.1016/j.bone.2006.11.001. Epub 2006 Dec 19. Bone. 2007. PMID: 17182297 Clinical Trial.

2

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

Siris ES, Harris ST, Eastell R, Zanchetta JR, Goemaere S, Diez-Perez A, Stock JL, Song J, Qu Y, Kulkarni PM, Siddhanti SR, Wong M, Cummings SR; Continuing Outcomes Relevant to Evista (CORE) Investigators. Siris ES, et al. Among authors: wong m. J Bone Miner Res. 2005 Sep;20(9):1514-24. doi: 10.1359/JBMR.050509. Epub 2005 May 16. J Bone Miner Res. 2005. PMID: 16059623 Free article. Clinical Trial.

3

Relationships between bone mineral density and incident vertebral fracture risk with raloxifene therapy.

Sarkar S, Mitlak BH, Wong M, Stock JL, Black DM, Harper KD. Sarkar S, et al. Among authors: wong m. J Bone Miner Res. 2002 Jan;17(1):1-10. doi: 10.1359/jbmr.2002.17.1.1. J Bone Miner Res. 2002. PMID: 11771654 Free article. Clinical Trial.

4

Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint.

Marcus R, Wong M, Heath H 3rd, Stock JL. Marcus R, et al. Among authors: wong m. Endocr Rev. 2002 Feb;23(1):16-37. doi: 10.1210/edrv.23.1.0453. Endocr Rev. 2002. PMID: 11844743 Review.

5

Comparison of fracture, cardiovascular event, and breast cancer rates at 3 years in postmenopausal women with osteoporosis.

Silverman SL, Delmas PD, Kulkarni PM, Stock JL, Wong M, Plouffe L Jr. Silverman SL, et al. Among authors: wong m. J Am Geriatr Soc. 2004 Sep;52(9):1543-8. doi: 10.1111/j.1532-5415.2004.52420.x. J Am Geriatr Soc. 2004. PMID: 15341559

6

Raloxifene reduces risk of vertebral fractures [corrected] in postmenopausal women regardless of prior hormone therapy.

Johnell O, Cauley JA, Kulkarni PM, Wong M, Stock JL. Johnell O, et al. Among authors: wong m. J Fam Pract. 2004 Oct;53(10):789-96. J Fam Pract. 2004. PMID: 15469774 Clinical Trial.

7

Similar proportions of women lose bone mineral density with raloxifene or alendronate treatment.

Adachi JD, Adami S, Kulkarni PM, Wong M, Stock JL. Adachi JD, et al. Among authors: wong m. J Clin Densitom. 2005 Fall;8(3):273-7. doi: 10.1385/jcd:8:3:273. J Clin Densitom. 2005. PMID: 16055956 Clinical Trial.

8

The effect of raloxifene therapy on the risk of new clinical vertebral fractures at three and six months: a secondary analysis of the MORE trial.

Qu Y, Wong M, Thiebaud D, Stock JL. Qu Y, et al. Among authors: wong m. Curr Med Res Opin. 2005 Dec;21(12):1955-9. doi: 10.1185/030079905X75032. Curr Med Res Opin. 2005. PMID: 16368046 Clinical Trial.

9

The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety.

Stovall DW, Utian WH, Gass ML, Qu Y, Muram D, Wong M, Plouffe L Jr. Stovall DW, et al. Among authors: wong m. Menopause. 2007 May-Jun;14(3 Pt 1):510-7. doi: 10.1097/GME.0b013e318031a83d. Menopause. 2007. PMID: 17314736 Clinical Trial.

10

Severity of prevalent vertebral fractures and the risk of subsequent vertebral and nonvertebral fractures: results from the MORE trial.

Delmas PD, Genant HK, Crans GG, Stock JL, Wong M, Siris E, Adachi JD. Delmas PD, et al. Among authors: wong m. Bone. 2003 Oct;33(4):522-32. doi: 10.1016/s8756-3282(03)00241-2. Bone. 2003. PMID: 14555255 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

8,780 results

Search Page

Filters